Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+

  Hepatitis C

  Free Subscription


1 Ann Intern Med
2 Lancet Infect Dis
2 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Intern Med

  1. GORDON CE, Berenguer MC, Doss W, Fabrizi F, et al
    Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline.
    Ann Intern Med. 2019 Sep 24. pii: 2751913. doi: 10.7326/M19-1539.
    PubMed     Text format     Abstract available

    Lancet Infect Dis

  2. ZALLER N, Ostrach B
    HCV, injection drug use, and the importance of harm reduction in Kenya.
    Lancet Infect Dis. 2019 Sep 17. pii: S1473-3099(19)30407.
    PubMed     Text format    

  3. AKIYAMA MJ, Cleland CM, Lizcano JA, Cherutich P, et al
    Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
    Lancet Infect Dis. 2019 Sep 17. pii: S1473-3099(19)30264.
    PubMed     Text format     Abstract available

    PLoS One

  4. MANGIA A, Piazzolla V, Giannelli A, Visaggi E, et al
    Correction: SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience.
    PLoS One. 2019;14:e0223287.
    PubMed     Text format     Abstract available

  5. LONDONO MC, Riveiro-Barciela M, Ahumada A, Munoz-Gomez R, et al
    Effectiveness, safety/tolerability of OBV/PTV/r +/- DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
    PLoS One. 2019;14:e0221567.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis C is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.